Research programme: Bruton's tyrosine kinase inhibitors - Pharmacyclics

Drug Profile

Research programme: Bruton's tyrosine kinase inhibitors - Pharmacyclics

Alternative Names: PCI-45261; PCI-45292

Latest Information Update: 28 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacyclics
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Hypersensitivity; Rheumatoid arthritis

Most Recent Events

  • 26 May 2015 Pharmacyclics has been acquired by AbbVie
  • 31 Mar 2014 A lead candidate Btk inhibitor has entered clinical development for Rheumatoid arthritis in the USA
  • 31 Jan 2014 Pharmacyclics files an IND application with the FDA in USA for Inflammation and Autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top